Press release

Nomination Committee for the 2026 Annual General Meeting in Nanexa AB (publ)

The Nomination Committee for the Annual General Meeting 2026 in Nanexa AB (publ) has been appointed.

The members of the Nomination Committee are:

Marlon Värnik, Exelity
Jonas Pålsson
Göran Ando, Chairman of the Board, adjunct

The Nomination Committee's proposals will be presented in the notice to the 2026 Annual General Meeting and on the company's website, www.nanexa.com.

Shareholders may contact the Nomination Committee with suggestions regarding its work by sending e-mail to info@nanexa.se (heading "Nanexa's Nomination Committee") or by letter to: Nanexa AB, Attn: Nanexa's Nomination Committee, Virdings Allé 2, SE-754 50, Uppsala, Sweden.

The Annual General Meeting will be held in Uppsala on 12 May 2026.

For further information, please contact:

About Nanexa AB (publ)

Nanexa is bringing the control, precision and versatility of Atomic Layer Deposition (ALD) technology to drug formulation. The company’s proprietary PharmaShell® platform is a unique drug delivery system that enables a high drug load, thus low injection volume, creating a new generation of ‘super generic’ formulations that will provide greater convenience and reduce costs in the treatment of conditions such as metabolic diseases like type 2 diabetes and obesity, hematology/oncology, cardiovascular disorders, psychiatry, and many others.
Nanexa develops its own products and also has collaboration agreements with several pharma companies, including the latest license and option agreement with Moderna.

Nanexa’s share is listed on Nasdaq First North Growth Market in Stockholm (NANEXA).